Log In
BCIQ
Print this Print this
 

oxymetazoline (AGN-199201) (formerly V-101)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionTopical cream targeting alpha adrenergic receptors on small blood vessels
Molecular Target Adrenergic receptor alpha 1 (ADRA1) ; Adrenergic receptor alpha 2 (ADRA2)
Mechanism of ActionAdrenergic receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationRosacea
Indication DetailsTreat erythema in patients with rosacea
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$75.0M

$200.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/19/2011

Undisclosed

$75.0M

$200.0M

Get a free BioCentury trial today